JP2024529457A5 - - Google Patents

Info

Publication number
JP2024529457A5
JP2024529457A5 JP2024505007A JP2024505007A JP2024529457A5 JP 2024529457 A5 JP2024529457 A5 JP 2024529457A5 JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024529457 A5 JP2024529457 A5 JP 2024529457A5
Authority
JP
Japan
Prior art keywords
cancer
composition
composition according
bacteria
attenuated bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529457A (ja
Filing date
Publication date
Priority claimed from EP21188352.5A external-priority patent/EP4124342A1/en
Application filed filed Critical
Publication of JP2024529457A publication Critical patent/JP2024529457A/ja
Publication of JP2024529457A5 publication Critical patent/JP2024529457A5/ja
Pending legal-status Critical Current

Links

JP2024505007A 2021-07-28 2022-07-28 生弱毒化細菌を用いたがん療法 Pending JP2024529457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188352.5A EP4124342A1 (en) 2021-07-28 2021-07-28 Cancer therapy with live attenuated bacteria
EP21188352.5 2021-07-28
PCT/EP2022/071198 WO2023006879A1 (en) 2021-07-28 2022-07-28 Cancer therapy with live attenuated bacteria

Publications (2)

Publication Number Publication Date
JP2024529457A JP2024529457A (ja) 2024-08-06
JP2024529457A5 true JP2024529457A5 (https=) 2025-05-21

Family

ID=77126585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505007A Pending JP2024529457A (ja) 2021-07-28 2022-07-28 生弱毒化細菌を用いたがん療法

Country Status (7)

Country Link
US (2) US12171791B2 (https=)
EP (2) EP4124342A1 (https=)
JP (1) JP2024529457A (https=)
CN (1) CN117729929A (https=)
AU (1) AU2022318153A1 (https=)
CA (1) CA3226844A1 (https=)
WO (1) WO2023006879A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118045167A (zh) * 2024-02-18 2024-05-17 绍兴越然生物医药科技有限公司 抗肿瘤复合疫苗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20070298012A1 (en) 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
CA2714276A1 (en) 2008-02-05 2009-08-13 Aeterna Zentaris Gmbh Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof
GB0900350D0 (en) 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
EP3495469A1 (en) 2017-12-07 2019-06-12 Prokarium Limited Vaccine compositions ii

Similar Documents

Publication Publication Date Title
Sedighi et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
Cao et al. Bacteria and bacterial derivatives as drug carriers for cancer therapy
Raja et al. Oncolytic virus immunotherapy: future prospects for oncology
Zheng et al. Targeted cancer therapy using engineered Salmonella typhimurium
Lee et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial
Patyar et al. Bacteria in cancer therapy: a novel experimental strategy
Chorobik et al. Salmonella and cancer: from pathogens to therapeutics
JP2019504105A5 (https=)
Benitez et al. Mycobacterium bovis BCG in metastatic melanoma therapy
KR20160022803A (ko) 암 치료
JP2022530044A5 (https=)
Garnett-Benson et al. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities
JP2020511139A5 (https=)
JP2024529457A5 (https=)
JP2024512775A5 (https=)
Sun et al. Combination therapy with oncolytic viruses for lung cancer treatment
JP2018509423A5 (https=)
Shi et al. Systematic review on the role of the gut microbiota in tumors and their treatment
Zhao et al. Biomimetic “Trojan Horse” delivery of traditional Chinese medicine with immunogenic hybrid vesicles of bacterial outer membrane and tumor cell membrane for synergistic chemo-immunotherapy of liver cancers
JP2020507332A5 (https=)
Shahbaz et al. Current advances in microbial-based cancer therapies
JP2017515806A5 (https=)
US20200237904A1 (en) Methods and Compositions Useful for Treating Cancer
Hernandez-Alcoceba et al. Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives
Yang et al. Oncolytic virus for cancer immunotherapy